{
    "title": "Blow to AstraZeneca as lung cancer drug Imfinzi fails key clinical trial",
    "url": "https://www.dailymail.co.uk/money/markets/article-12748869/Blow-AstraZeneca-lung-cancer-drug-Imfinzi-fails-key-clinical-trial.html",
    "date": "2023-11-14",
    "keywords": [
        "cancer",
        "trial",
        "drug",
        "share",
        "account",
        "fund",
        "imfinzi",
        "blow",
        "group",
        "glencore",
        "money",
        "diy",
        "investment",
        "fee",
        "astrazenecas",
        "trialastrazeneca",
        "trialthe",
        "ftse",
        "pharma",
        "soriot",
        "treatment",
        "goal",
        "stage",
        "nonsmall",
        "cell",
        "lung",
        "chemotherapyastrazeneca",
        "improvement",
        "alonewe",
        "galbraith",
        "head",
        "oncology",
        "researchastrazeneca",
        "cent",
        "tract",
        "carcinoma",
        "type",
        "cirrhosis",
        "organ",
        "damagelast",
        "week",
        "race",
        "deal",
        "firm",
        "eccogene",
        "brummer",
        "city",
        "control",
        "coowner",
        "coal",
        "arm",
        "teck",
        "article",
        "capital",
        "risk",
        "isa",
        "trade",
        "month",
        "community",
        "model",
        "affiliate",
        "product",
        "commission",
        "editorial",
        "independence",
        "investing",
        "platform"
    ],
    "category": [
        "money",
        "markets"
    ]
}